LIMES Schlosskliniken (LIK) H1 2025 earnings summary

Executive summary

• Revenues rose 28% year-over-year to EUR 23.9 million, driven by higher patient days and strong clinic occupancy.

• EBITDA increased 77% to EUR 6.2 million, with an EBITDA margin of 26.1% versus 18.8% last year.

• EBIT more than doubled to EUR 4.9 million, and net income attributable to shareholders grew 81% to EUR 3.3 million.

• Two new clinics (Abtsee and Bergisches Land) began operations in July 2025, adding 180 treatment places.

• The group maintained a strong financial position with liquid assets of EUR 11.1 million.

Financial highlights

• Patient days increased 8.6% to 26,853, with average occupancy at 83% (up from 79%).

• Gross earnings (EBITDA) reached EUR 6.2 million, up 77% year-over-year.

• EBIT margin improved to 20.6% from 11.8% last year.

• Result per share rose to EUR 11.30, up 81% year-over-year.

• Cash flow from operating activities increased 48% to EUR 3.2 million.

Outlook and guidance

• Positive operating performance expected to continue in the second half of 2025.

• New clinics are projected to significantly boost revenue and contribute EUR 6 million to EBITDA in the medium term.

• Break-even for new clinics anticipated at the start of Q1 2026, with lower start-up costs due to compensation for delayed commissioning.